Great set of questions @Medify. I have to admit that if it wasn't for Bill's involvement (which has deepened) I would actually be more concerned about the current states of thing with Purifloh. I've seen so many companies (and sadly invested in some) who showed so much promise but showed so little for it and are now wallowing. The whole TB trial debacle was not a good look to be fair and the consistent teasing of OEM negotiations and testing both excites but also rings alarm bells. I am also surprised that there has been no traction at all for the stock on the OTCQX - I would have expected some US investors in the know to get on board (maybe they hold shares on the ASX).
But then you have to balance this out with the fact that we have Bill Parfet putting his full weight behind Purifloh. There is no doubt that the technology is potentially game changing but the risk is in the execution. Bill removes some of this risk.
It's a tricky investment I reckon and not risk free but a beauty if they can pull it off.
PO3 Price at posting:
$5.84 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
